Werewolf Therapeutics, Inc.
We are a preclinical biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional pro-inflammatory immune therapies. Our molecules, which we refer to as INDUKINETM molecules, are intended to selectively target the tumor microenvironment, or TME. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2, or IL-2, and Interleukin-12, or IL-12, respectively, INDUKINE molecules to treat solid tumors. We plan to submit an investigational new drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for WTX-124 and WTX-330 in the first half of 2022, and thereafter initiate a Phase 1/1b clinical trial for each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.
We are building our PREDATOR platform to generate a pipeline of innovative therapeutics that cover a diversity of immune stimulating mechanisms with the potential to address significant unmet medical need in cancer.
(Note: Werewolf Therapeutics upsized its IPO at pricing on April 29, 2021, to 7.5 million shares, up from 6.25 million shares in the prospectus, at $16 – the mid-point of its $15-to-$17 range – to raise
|Address||1030 Massachusetts Avenue, Suite 210 Cambridge, MA 02138|
|Phone Number||(617) 952-0555|
|View Prospectus:||Werewolf Therapeutics, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-15.04 mil (last 12 months)|
|Price range||$16.00 - $16.00|
|Est. $ Volume||$120.0 mil|
|Manager / Joint Managers||Jefferies/ SVB Leerink/ Evercore ISI|
|CO-Managers||H.C. Wainwright & Co.|
|Expected To Trade:||4/30/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|